Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...

Novo Nordisk stock fell after the drugmaker unexpectedly cuts its full-year guidance, citing lower sales expectations for its ...

Meshel Laurie has got candid about her whopping 60kg weight loss as she called for a controversial obesity medication to be added to the Pharmaceutical Benefits Scheme (PBS).

Ozempic and its counterparts, including Wegovy, Mounjaro and Zepbound, have surged in popularity as a means for weight loss, fueled by celebrity endorsements and slick pharmaceutical marketing.

People with diabetes who used semaglutide or other GLP-1 agonists were also less likely to see a provider for depression.